ERBB2 and breast cancer: Another review that aimed to assess outcomes among patients with early-stage HR-positive HER2-negative BC concluded that approximately one in six patients with node-positive disease experienced recurrence within five years of adjuvant endocrine therapy [58] (Figure 2).